1. Introduction {#sec1}
===============

Antimicrobial resistance (AMR) is a growing problem in the 21^st^ century and one of the most serious jeopardies to global public health \[[@B1]\]. The number of resistant microbial strains, geographic areas affected by drug resistance, and the extent of resistance in each organism are escalating \[[@B2]\]. Moreover, the percentages of organisms exhibiting AMR, especially resistance to multiple antibiotics, are continuingly increased \[[@B3]\]. Thus, disease agents that were once thought to be susceptible to antibiotics are returning in new leagues resistant to these therapies \[[@B4]\].

Resistant microorganisms lead to an increase in morbidity and mortality since it increases the risk of inappropriate therapy \[[@B5], [@B6]\]. This resistance may delay and hinder treatment, resulting in complications or even death \[[@B7], [@B8]\]. Moreover, a patient may need more care, as well as the use of alternative and more expensive antibiotics, which may have more severe side effects or may need more invasive treatments, such as intravenous injection, to be given in hospitals \[[@B6], [@B9]\].

Multiply resistant organisms render therapy more precarious and costly and sometimes unsuccessful. Individuals may succumb to multidrug resistance (MDR) infections because all available drugs have failed, especially in the developing world \[[@B10]\]. For instance, MDR enteric disease agents have threatened public health in developing countries \[[@B3]\]. Globally, MDR were reported in*Mycobacterium tuberculosis*,*Enterococcus faecium*,*Enterobacter cloacae*,*Klebsiella pneumoniae*,*Staphylococcus aureus*,*Acinetobacter baumanii,*and*Pseudomonas aeruginosa* \[[@B11]\].

Historically, many infections could be treated successfully according to the clinician\'s past clinical experience (i.e., empirical therapy) \[[@B12], [@B13]\]. However, this practice is becoming more than the exception to the rule since resistance has been observed to essentially all of the antimicrobial agents currently approved for use in human and veterinary clinical medicine. This, combined with the variety of antimicrobial agents currently available, makes the selection of an appropriate agent an increasingly more challenging task. Hence, this situation has made clinicians more dependent on data from*in vitro* antimicrobial susceptibility testing and highlights the importance of the diagnostic laboratory in clinical practice \[[@B14]\].

Data on AMR among local pathogens help define the best possible treatment for individual patients \[[@B15], [@B16]\]. However, the proportion of resistant bacteria can vary from one area to another \[[@B17]\], and in many health facilities there are no local data on resistance patterns \[[@B18]\]. Experiences from surveillance networks on antimicrobial use and AMR show that data, where available, can be put to multiple uses, including orienting treatment choices, understanding AMR trends, informing public health policy, identifying priority areas for interventions, and monitoring the impact of interventions to contain resistance \[[@B1]\]. However, there is no sufficient data on antimicrobial resistance profile of antibiotics especially in developing country like Ethiopia. Therefore, the present study involves the screening of the antimicrobial resistant profile of 3^rd^ generation cephalosporin drugs that are used in the treatment of infectious diseases in Jimma University Specialized Teaching Hospital.

2. Materials and Methods {#sec2}
========================

2.1. Study Design and Specimen Collection {#sec2.1}
-----------------------------------------

A hospital based cross-sectional study was conducted in Jimma University Specialized Hospital (JUSH) from April to August 2016. The hospital was selected because of the diverse services it provides for wide range of health problems of the patients who come from different parts of the country. The clinical samples such as wound swab, urine, sputum, and stool were collected from hospitalized patients by trained nurses.

2.2. Bacteria Identification {#sec2.2}
----------------------------

For the detection and isolation of pathogenic bacteria, all the clinical samples were collected by standard microbiological technique. Then, depending on the source of samples, each specimen was platted onto MacConkey agar, Blood agar, Mannitol Salt agar, Xylose lysine deoxycholate agar, Chocolate agar, and Thayer--Martin agar and then incubated aerobically at 37°C for 24 h.

Gram-positive cocci in cluster, both catalase and coagulase positivity, and characteristically yellow to golden colored colonies on blood agar coupled with mannitol fermentation on MSA were applied to identify*Staphylococcus aureus* from other gram-positive cocci. The gram-negative bacilli, the coliforms,*Proteus*spp.,*and Yersinia enterocolitica*were identified by standard microbiological algorisms such as gram\'s stain (gram-negative bipolarly stained bacilli for*Yersinia*spp) colonial growth characteristics and appearance on enriched and selective media indicated combined with standard biochemical tests outlined in the reference material \[[@B19]\]. Biochemical tests such as fermentation of lactose, glucose, and sucrose with and without H~2~S production (using TSI/KIA); lysine decarboxylation (LDC); indole and citrate utilization (MIS); methyl red (MR), Voges-Proskauer (VP); and pyrrolidonyl aminopeptidase (PYR) were used to identify the clinical isolates in question and of clinical significance \[[@B19], [@B20]\]. Thus, clinical strains of*Staphylococcus aureus, Escherichia Coli, Klebsiella pneumoniae, Proteus*species,*Citrobacter freundii, Citrobacter Koseri, Enterobacter cloacae, Klebsiella oxytoca, Enterobacter aerogenes,* and*Yersinia enterocolitica*were isolated from the collected clinical samples.

2.3. Antimicrobial Susceptibility Testing {#sec2.3}
-----------------------------------------

Antimicrobial susceptibility testing was done using disk diffusion technique according to Kirby--Bauer method using*S. aureus*  ATCC 25923 and as quality control strains \[[@B21]\]. Accordingly, at least three to five well-isolated colonies of the same morphological type were selected from an agar plate culture and transferred into Muller Hinton broth and incubated at 37°C for 24 hours. The turbidity of the suspension was adjusted with sterile saline to obtain turbidity optically comparable to that of the 0.5 McFarland standards. Then, the swab was streaked over the entire surface of the freshly prepared Mueller Hinton agar plate. The antimicrobial disks were applied to the plates within 15 minutes after inoculation. The plates were then incubated at 37°C for 24 hours. A zone of inhibition was measured and the results were interpreted as sensitive, resistant, or intermediate based on resistance data interpreted according to Clinical and Laboratory Standards Institute \[[@B22]\]. The antimicrobial agents tested were third-generation cephalosporin: ceftriaxone (30 *μ*g) and ceftazidime (CAZ) (30 *μ*g). Moreover, MDR profile for those strains resistant to cephalosporin drugs were determined against different classes of antimicrobials such as ciprofloxacin (5 *μ*g), sulfamethoxazole-trimethoprim (25 *μ*g), amikacin (AMK) (30 *μ*g), piperacillin (PIP) (100 *μ*g), Amox-clavulanic acid (AUG), and ciprofloxacin (CPR) (5*μ*g). All the antibiotic discs used were manufactured by Abtek Biologicals Ltd., Liverpool L9 7AR, UK.

2.4. Quality Control {#sec2.4}
--------------------

The reliability of the study findings was guaranteed by implementing quality control measures throughout the whole process of the laboratory work. Staining reagents, culture medias, and antibiotic discs were checked for their normal shelf life before use. All culture plates and antibiotic discs were stored at recommended refrigeration temperature after being prepared and sterilized by autoclaving at 121°C for 15 minutes. The standard reference bacterial strains were tested as a positive control on the biochemical tests and agar plates with antibiotic discs. Proper sample collection and handling were done by experienced nurses who were working at each ward unit.

2.5. Data Analysis {#sec2.5}
------------------

Data were edited, cleaned, entered, and analyzed using statistical package for social science (SPSS) version 16. Descriptive analysis such as frequencies and mean were used. P value of \< 0.05 was considered to indicate statistically significant differences and the results were presented using tables and figure.

3. Results {#sec3}
==========

About 388 clinical specimens were collected from sputum, urine, wound swab, and stool of hospitalized patients having clinically evident infection (patients with complaints of urinary tract infection, open wounds, pneumonia, and upper respiratory tract infections). Totally, 248 (64%) bacterial isolates were obtained from 154 (62.1%) male and 94 (37.9%) female study subjects. In the present study*Escherichia coli* (25.4%) and*Staphylococcus aureus* (19.0 %) were the predominant organisms isolated from the study subjects. The other bacterial isolates include*Citrobacter freundii*(12.1%)*, Citrobacter koseri*(8.5%)*, Enterobacter cloacae*(13.0%),*Klebsiella oxytoca*(2.4%),*Klebsiella pneumoniae*(10.5%)*, Enterobacter aerogenes*(4.8%)*, Proteus*species (2.0%), and*Yersinia enterocolitica*(2.4%) as indicated in [Table 1](#tab1){ref-type="table"}.

All the bacterial isolates were tested for susceptibility against selected third-generation cephalosporins (ceftriaxone and ceftazidime). Out of 248 bacterial isolates, 140 (56.5%) were found to be resistant to ceftriaxone. But, 37 (14.9%) and 71 (28.6%) of the isolates remain intermediate and susceptible to ceftriaxone, respectively. On the other hand, 149 (60.1%) of the total bacterial isolates were found to be resistant, 53 (21.4%) were intermediate, and only 46 (18.5%) were susceptible to ceftazidime ([Figure 1](#fig1){ref-type="fig"}).

As shown in Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}, the rate of bacterial isolates resistant to ceftriaxone and ceftazidime was 56.5% and 60.1%, respectively. Majority of the urinary tract isolates were found to be resistant to the action of third-generation cephalosporins (ceftriaxone or ceftazidime). Out of 63*Escherichia coli* isolates, 46 (73%) were resistant to ceftriaxone which is very high. Moreover, about 41 (65%) of them were resistant to ceftazidime.*Citrobacter freundii,*which is another urinary pathogen, showed a resistance of 36.7% (11/30) to ceftriaxone and 43.3% (13/30) to ceftazidime.

In this study, most of the Enterobacteriaceae (*Citrobacter koseri*,*Enterobacter cloacae*,*Klebsiella oxytoca*,*Enterobacter aerogenes,*and*Proteus* species) isolates were resistant to ceftriaxone or ceftazidime. In addition,*Staphylococcus aureus*, which accounted 19% of total bacterial isolates, showed 23.4% (11/47) and 34% (16/47) resistance to ceftriaxone and ceftazidime, respectively. Similarly,*Klebsiella pneumoniae*showed 46.1% (12/26) resistance to ceftriaxone. More than 90% (10/11) of*Enterobacter aerogenes* were resistant to ceftazidime and none of the*Proteus* species were susceptible to the action of ceftriaxone or ceftazidime.

The multidrug resistance pattern showed that among the bacterial strains found to be resistant to ceftriazone and ceftazidime about 109 (44%) and 108 (43.5%) were resistant to two, three, or four drugs, respectively.*Escherichia coli, Staphylococcus aureus, Enterobacter* species, and*Citrobacter* species showed resistance to two, three, or four drugs. On the other hand,*Citrobacter* species and*Proteus* species were resistant to two or three drugs while*Klebsiella Pneumonia* revealed resistance to two drugs.

4. Discussion {#sec4}
=============

The widespread use of brood spectrum antibiotics has led to the emergence of antibiotic resistant strains of bacteria. High rates of resistance have been primarily observed in bacteria that cause common health problems. In the present study more than half of the isolated bacteria strains were resistant to either ceftriaxone or ceftazidime drugs which is in agreement with 2014 WHO reports \[[@B1]\].

The drug resistance pattern differences among isolates based on various characteristics were evaluated ([Table 2](#tab2){ref-type="table"}). In view of that, there were no significant differences observed except for the specimen types from which the strains were isolated. Most of the urinary tract isolates were found to be resistant to the action of third-generation cephalosporins (ceftriaxone or ceftazidime). The majority of these isolates were*Escherichia coli* which is a gram-negative bacterium. This uropathogen is the major extended spectrum beta-lactamase (ESBL) producer, severely limiting the therapeutic management in cases of urinary tract infections \[[@B23]\]. Hence, isolates of these strains have relatively high potentials of developing resistance \[[@B12]\].

Moreover, most of*Escherichia coli* strains isolated from the whole specimen were found to be resistant to the action of ceftriaxone and ceftazidime in the present study. It was also revealed that the proportion of resistance to third-generation cephalosporins increased significantly for*Escherichia coli* infections since 2004 \[[@B24]\]. Similarly, other research finding reported that*Escherichia coli* exhibited the highest resistance to ceftazidime and ceftriaxone \[[@B25], [@B26]\]. However, the study in University of Gondar Hospital, Ethiopia, showed that the percentage of resistance strains observed against ceftazidime was high but relatively less to ceftriaxone \[[@B27]\].

The majority of*Klebsiella pneumoniae* strains were more resistant to ceftazidime compared to ceftriazone in this study. However, it is dissimilar with other studies which showed that the isolates exhibited similar resistance pattern to both ceftazidime and ceftriaxone \[[@B28], [@B29]\]. It was also reported that*Klebsiella pneumoniae* strain isolated from patients with community acquired pneumonia was resistant to third-generation cephalosporins \[[@B30], [@B31]\]. This is because these strains have a *β*-lactam ring provided with a Zwitterionic structure that protects these antibiotics from hydrolysis by *β*-lactamases \[[@B32]\]. On the contrary, the study conducted in Oman stated that most of the isolated strains were susceptible towards third-generation cephalosporin-ceftriaxone \[[@B33]\].

*Staphylococcus aureus*strains were found to be more susceptible than other bacteria strains to ceftriaxone and ceftazidime which is inconsistent with previous study in which most of the strains were resistant \[[@B34]\]. However, it is in line with other studies conducted in different areas which reported the susceptibility of the strains towards the third-generation cephalosporins \[[@B33], [@B35], [@B37]\]. On the other hand, in the study carried out in Dessie Hospital, Ethiopia, the resistance pattern for clinical isolate against ceftriazone was about 43.5% which is more than the present study. These findings indicate that the resistance rate of*Staphylococcus aureus*varies from area to area or/and period to period even within the same country.

Most of the Enterobacteriaceae (*Citrobacter koseri, Enterobacter cloacae, Klebsiella oxytoca*,*Enterobacter aerogenes,*and*Proteus*species) tested isolates were resistant to ceftriaxone or ceftazidime. Similarly,*in vitro* antimicrobial study in Senegal revealed that most of the isolated Enterobacteriaceae strains were resistant to third-generation cephalosporins \[[@B37]\]. On the other hand, it was reported that*Enterobacter* species were relatively more resistant to ceftriaxone than ceftazidime \[[@B38]\]. Similar resistance pattern with present study was reported for*Enterobacter cloacae*against ceftriazone \[[@B39]\].

Multidrug resistance pattern of isolated strains, which were found to be resistant to either of ceftriaxone and ceftazidime, was also evaluated. The majority of*Escherichia coli* and*Staphylococcus aureus* strains exhibited resistance against two, three, or four antimicrobials. About half of*Escherichia coli* strains resistant to third-generation cephalosporins were also resistant to clinically used drugs such as amikacin, sulfamethoxazole-trimethoprim, piperacillin, and ciprofloxacin. This could be due to the high rate of adaptive mutation. Resistant organisms transfer their resistant genes either to their offspring by replication (vertical gene transfer) or by conjugation where the plasmids carrying the resistant gene are exchanged between the nearby organisms (horizontal gene transfer) \[[@B1], [@B40]\].

5. Conclusion {#sec5}
=============

Microbial resistance to third-generation cephalosporin drugs have been increasing significantly as the finding of the present study indicated. Moreover, those strains which developed resistance to third-generation cephalosporins were also resistant to multiple drugs which could make treatment of infectious disease triggered by these microbial strains become challenging ([Table 5](#tab5){ref-type="table"}). Therefore, the right medications should be selected based on susceptibility data of causative agents towards the drugs for the treatment of right disease agents.
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###### 

Distribution of isolates in clinical specimens collected from patients.

  **Clinical isolates**       **Specimen type**                  
  --------------------------- ------------------- ---- ---- ---- -----
  *Escherichia coli*          \-                  29   3    31   63
  *Citrobacter*spp.           3                   11   25   12   51
  *Enterobacter species*      16                  13   15   \-   44
  *Klebsiella oxytoca*        \-                  \-   6    \-   6
  *Klebsiella pneumonia*      23                  \-   \-   3    26
  *Staphylococcus aureus*     6                   3    38   \-   47
  *Proteus species*           \-                  \-   5    \-   5
  *Yersinia enterocolitica*   3                   \-   3    \-   3
  **Total**                   51                  56   95   46   248

###### 

Sociodemographic characteristics association with resistance pattern of clinical isolates.

  **Characteristics**   **Ceftazidime**   **Ceftriaxone**                            
  --------------------- ----------------- ----------------- ---- --------- ---- ---- ---------
  **Age in years**      ≤19               23                20   0.07622   23   20   0.06902
                        20-64             80                61             73   68    
                        ≥65               46                18             44   20    
                                                                                     
  **Sex**               Female            55                39   0.69326   53   41   0.98641
                        Male              94                60             87   67    
                                                                                     
  **Specimen Type**     Sputum            29                22   0.08527   26   25   0.01426
                        Urine             41                15             41   15    
                        Wound Swab        50                45             45   50    
                        Stool             29                17             28   18    
                                                                                     
  **Hospital Stay**     ≤1 Days           35                27   0.29227   30   32   0.35481
                        2-3 Days          72                40             66   46    
                        4-6 Days          19                20             21   18    
                        ≥7 Days           23                12             23   12    

###### 

Resistance pattern of the different clinical isolates to ceftriaxone.

  **Clinical isolates**    **Resistance pattern**                                    
  ------------------------ ------------------------ ---------------- --------------- ---------------
  *Citrobacter species*    27(52.9%)                13(25.5%)        11(21.6%)       **51**
  *E. coli*                46 (73.0%)               3 (4.8%)         14 (22.2%)      **61**
  *Enterobacter species*   31 (70.4)                5(11.4%)         8(18.2%)        **44**
  *K. pneumonia*           12 (46.2%)               4 (15.4%)        10 (38.4%)      **26**
  *K. oxytoca*             5 (83.3%)                0                1 (16.7%)       **6**
  *S. aureus*              11 (4.4%)                10(4.0%)         26(10.5%)       **47**
  *Proteus species*        4 (80%)                  1 (20%)          0               **5**
  *Y. enterocolitica*      4 (66.6%)                1 (16.7%)        1 (16.7%)       **6**
  **Total**                **140 (56.5)**           **37 (14.9%)**   **1 (16.7%)**   **248 (100)**

###### 

Resistance pattern of the different clinical isolates to ceftazidime.

  **Clinical isolates**    **Resistance pattern**                                     
  ------------------------ ------------------------ ---------------- ---------------- ---------------
  *E. coli*                41 (65.1%)               10 (15.9%)       12 (19.0%)       **63**
  *Citrobacter species*    29 (56.9%)               8 (15.7%)        14 (27.4%)       **51**
  *S. aureus*              16 (34.0%)               20 (42.6%)       11 (23.4%)       **47**
  *Enterobacter species*   35 (79.6%)               6 (13.6%)        3(6.8%)          **44**
  *K. pneumonia*           19 (73.1%)               5 (19.2%)        2 (7.7%)         **26**
  *K. oxytoca*             4 (80%)                  2 (20%)          0                **6**
  *Y. enterocolitica*      2 (33.3%)                0                4 (66.7%)        **6**
  *Proteus species*        3 (60.0%)                2 (40.0%)        0                **5**
  **Total**                **149 (60.1%)**          **53 (21.4%)**   **46 (18.5%)**   **248 (100)**

###### 

Multidrug resistance pattern of microbial strains.

  ----------------------------------------------------------------------------------------------------
  **Clinical Isolates**                **Multi-drug resistance pattern**                          
  ------------------------------------ ----------------------------------- ---- ----------------- ----
  ***Escherichia coli(n=63)***         CTR only                            46   CAZ only          41

                                       CTR, SXT                            42   CAZ+SXT           36

                                       CTR,SXT,AUG                         21   CAZ+SXT+AUG       20

                                       CTR,SXT,AUG,CPR                     20   CAZ,SXT,AUG,CPR   19

                                                                                                  

  ***Klebsiella Pneumonia (n=26)***    CTR only                            12   CAZ only          19

                                       CTR,CPR                             3    CAZ,CPR           3

                                       CTR,CPR,AMK                         0    CAZ,CPR,AMK       0

                                                                                                  

  ***Staphylococcus aureus (n=47)***   CTR only                            11   CAZ only          16

                                       CTR,CPR                             6    CAZ,CPR           7

                                       CTR,CPR,AUG                         2    CAZ,CPR,AUG       2

                                                                                                  

  ***Citrobacter species*** \          CTR only                            27   CAZ only          29
  ***(n=51)***                                                                                    

                                       CTR,PIP                             25   CAZ,PIP           27

                                       CTR,PIP,CPR                         9    CAZ,PIP,CPR       9

                                       CTR,PIP,CPR,AMK                     1    CAZ,PIP,CPR,AMK   0

                                                                                                  

  ***Enterobacter species*** \         CTR only                            32   CAZ only          36
  ***(n=44)***                                                                                    

                                       CTR,PIP                             30   CAZ,PIP           33

                                       CTR,PIP,CPR                         13   CAZ,PIP,CPR       14

                                       CTR,PIP,CPR,AMK                     1    CAZ,PIP,CPR,AMK   1

                                                                                                  

  ***Proteus species*** \              CTR only                            4    CAZ only          3
  ***(n=5)***                                                                                     

                                       CTR+PIP                             3    CAZ+PIP           2

                                       CTR,PIP,CPR                         1    CAZ+PIP+CPR       1

                                       CTR,PIP,CPR,AMK                     0    CAZ,PIP,CPR,AMK   0
  ----------------------------------------------------------------------------------------------------

CTR= ceftriaxone, SXT = sulfamethoxazole-trimethoprim, AMK= amikacin,, PIP= piperacillin, CAZ= ceftazidime,, AUG= Amox-clavulanic acid, and CPR= ciprofloxacin.
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